## SDGR: Schrodinger, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.9% below STRENGTH zone (3.0-6.0%); PEG 1.30 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($16.43)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Why (SDGR) Price Action Is Critical for Tactical Trading**
- Source: Stock Traders Daily | 20251211T214600 | Neutral | Relevance: 100%
- The article analyzes Schrodinger Inc. (NASDAQ: SDGR), highlighting mixed sentiment and a mid-channel oscillation pattern that suggests choppiness. It identifies an exceptional risk-reward short setup and outlines three distinct trading strategies (Position, Momentum Breakout, Risk Hedging) tailored to different risk profiles. The analysis also provides multi-timeframe signal insights, including support and resistance levels for near-term, mid-term, and long-term horizons.

**2. Wall Street Analysts Believe Schrodinger (SDGR) Could Rally 46.17%: Here's is How to Trade**
- Source: Your Wyoming Link | 20251213T120914 | Bullish | Relevance: 100%
- Wall Street analysts project a potential upside of 46.2% for Schrodinger (SDGR), with a mean price target of $26.5. Despite skepticism around price targets, analysts' increasing optimism regarding the company's earnings prospects and a Zacks Rank #2 (Buy) suggest a potential rally in the stock. Investors are advised to consider earnings estimate revisions and the Zacks Rank as more reliable indicators than just price targets.

**3. Wall Street Analysts Believe Schrodinger (SDGR) Could Rally 46.17%: Here's is How to Trade**
- Source: Yahoo Finance | 20251212T085500 | Somewhat-Bullish | Relevance: 100%
- Wall Street analysts project a 46.17% rally for Schrodinger (SDGR) with a mean price target of $26.5. Despite potential over-optimism in analyst targets, a strong consensus on higher earnings estimates, coupled with a Zacks Rank #2 (Buy), suggests a legitimate upside for the stock. Investors are advised to use price targets as a starting point for further research, not as the sole basis for investment decisions.

**4. ARK Investment Acquires Additional Shares of Schrodinger (SDGR)**
- Source: GuruFocus | 20251212T020921 | Somewhat-Bullish | Relevance: 100%
- ARK Investment Management, led by Cathie Wood, has increased its stake in Schrodinger (SDGR) by acquiring an additional 36,600 shares, signaling continued confidence in the company's growth potential. Schrodinger, a healthcare software company with a market cap of approximately $1.34 billion, specializes in software solutions for drug discovery and has both software and drug discovery segments. Despite a mixed financial picture including profitability challenges and an Altman Z-Score indicating distress, the company shows strong liquidity and its P/S ratio suggests potential undervaluation, with analysts targeting a significant upside.

**5. Schrodinger, Inc. $SDGR Shares Purchased by Nikko Asset Management Americas Inc.**
- Source: MarketBeat | 20251214T110844 | Neutral | Relevance: 97%
- Nikko Asset Management Americas Inc. increased its stake in Schrodinger, Inc. (NASDAQ:SDGR) by 7.2% in the second quarter, owning over 2.59 million shares worth $52.09 million. Other institutional investors like Rubric Capital Management LP and UBS AM also significantly boosted their holdings. The article also notes recent analyst rating changes and an insider stock sale by Margaret Dugan.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.03M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 70.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Blackrock Inc.: 14.8% (-2.2%)
- Gates Foundation Tru: 10.8% (0.0%)
- Vanguard Group Inc: 9.8% (-4.2%)
- Rubric Capital Manag: 8.2% (+5.4%)
- Sumitomo Mitsui Trus: 7.1% (+24.8%)

### Key Risks

1. High short interest (25.5%, 10.0 days to cover): squeeze risk or crowded bearish bet.
2. Long-term trend broken: trading 13.5% below SMA200.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- Momentum building: MRS_10 improving +2.5% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.30 suggests fair value with growth premium. Balance sheet: strong liquidity (3.2x). Revenue growth strong at 20% YoY. Institutional flow bullish (5 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $1.3B |
| Beta | 1.57 |
| 52W Range | $15.99 - $28.47 |
| Short Interest | 25.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.30 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 strengthening from 0.4% to 2.9% (+2.5% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.1pp (needs >3.0% for momentum thesis). MRS_5 at 2.0% confirms short-term momentum alignment. Outperforming sector by 3.2pp, stock-specific strength. Below SMA200 (0.86x), long-term trend not supportive. RSI neutral at 50. OFD pattern: -DUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.90% (CS: 63) | Neutral |
| RSI_14 | 49.9 | Neutral |
| MACD Histogram | 0.20 | Bullish |
| vs SMA20 | 1.035x | Above |
| vs SMA50 | 0.946x | Below |
| vs SMA200 | 0.865x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $18.05
- **Stop Loss:** $16.43 (9.0% risk)
- **Target:** $19.67 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 617
- **Position Value:** $11,136.85
- **Portfolio %:** 11.14%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-25 (Est: $-0.17)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.74 | $-0.57 | +23.0% |
| 2025Q2 | $-0.64 | $-0.65 | -1.6% |
| 2025Q1 | $-0.81 | $-0.64 | +21.0% |
| 2024Q4 | $-0.38 | $-0.24 | +36.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*